Nod from Mexico, a boost for Biocon

| Updated on January 23, 2018 Published on April 09, 2015


Shares of Biocon will remain in focus on Friday, as the company strengthens its presence in Mexico. In a post-market hour disclosure, Biocon said it has received approval from Cofepris, the Mexican health authority, for insulin glargine through its partner PiSA Farmaceutica. Through the tie-up, Biocon will introduce Galactus, the long acting insulin glargine in Mexico, which has a disease prevalence of 12 per cent, the second highest in the world.

Published on April 09, 2015
This article is closed for comments.
Please Email the Editor